Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement, what specific patents and products are involved, what royalties are being sought, and how do these lawsuits fit into the broader landscape
Here is a comprehensive, cited breakdown. Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
District Court for the District of New Jersey [2][5][6].
The cases are: Translate Bio Inc.
Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringementAI-generated editorial hero image for Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement. Article summary: Here is a comprehensive, cited breakdown.. Topic tags: general web, code, security, regulation, manufacturing. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake numbers, clickbait thumbnails, icons, and tiny thumbnail layouts. Make it useful as an illustrative visual, not as factual evidence.
openai.com
Here is a comprehensive, cited breakdown.
Sanofi's Lawsuits Against Moderna and Pfizer
On July 14, 2026, Sanofi, through its mRNA-focused subsidiary Translate Bio, filed two separate patent infringement lawsuits in the U.S. District Court for the District of New Jersey . The cases are:
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement, what specific patents and products are involved, what royalties are being sought, and how do these lawsuits fit into the broader landscape"?
Here is a comprehensive, cited breakdown.
What are the key points to validate first?
Here is a comprehensive, cited breakdown. Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
What should I do next in practice?
District Court for the District of New Jersey [2][5][6].
Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement, what specific patents and products are involved, what royalties are being sought, and how do these lawsuits fit into the broader landscape
Here is a comprehensive, cited breakdown. Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
District Court for the District of New Jersey [2][5][6].
The cases are: Translate Bio Inc.
Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringementAI-generated editorial hero image for Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement. Article summary: Here is a comprehensive, cited breakdown.. Topic tags: general web, code, security, regulation, manufacturing. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake numbers, clickbait thumbnails, icons, and tiny thumbnail layouts. Make it useful as an illustrative visual, not as factual evidence.
openai.com
Here is a comprehensive, cited breakdown.
Sanofi's Lawsuits Against Moderna and Pfizer
On July 14, 2026, Sanofi, through its mRNA-focused subsidiary Translate Bio, filed two separate patent infringement lawsuits in the U.S. District Court for the District of New Jersey . The cases are:
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Search & fact check with cited sources for What legal actions has Sanofi taken against Moderna and Pfizer regarding mRNA patent infringement, what specific patents and products are involved, what royalties are being sought, and how do these lawsuits fit into the broader landscape"?
Here is a comprehensive, cited breakdown.
What are the key points to validate first?
Here is a comprehensive, cited breakdown. Sanofi's Lawsuits Against Moderna and Pfizer On July 14, 2026, Sanofi, through its mRNA focused subsidiary Translate Bio , filed two separate patent infringement lawsuits in the U.S.
What should I do next in practice?
District Court for the District of New Jersey [2][5][6].
Translate Bio Inc. v. Moderna Inc. — No. 2:26-cv-08690
Translate Bio Inc. v. Pfizer Inc. — No. 2:26-cv-08697
Sanofi stated it is "seeking fair compensation for use of its patented technology" and is not seeking to block sales of any vaccines .
Specific Patents and Products Involved
Patents asserted: Sanofi alleges that Moderna's and Pfizer's vaccines infringe up to 10 patents held by Translate Bio covering core mRNA delivery technologies . The patents specifically relate to:
Lipid nanoparticle (LNP) compositions and methods for mRNA delivery — Translate Bio holds multiple patents on LNP manufacturing processes, including low-citrate-concentration encapsulation, ambient-temperature formulation, and pre-formed LNP mixing techniques .
mRNA purification technologies — additional patents covering how mRNA is purified for use in vaccines .
Products accused of infringement:
Moderna: Spikevax and mNexspike (both COVID-19 vaccines) and mResvia (RSV vaccine) .
Pfizer: Comirnaty (the COVID-19 vaccine co-developed with BioNTech) .
Royalties and Damages Being Sought
No fixed royalty percentage or specific dollar amount has been publicly disclosed in the complaints. Sanofi's position, per a spokesperson, is that it is seeking "fair compensation" for use of its patented technology . However, the damages at stake are enormous — the vaccines named have generated tens of billions of dollars in cumulative revenue, and Sanofi's Life Sciences IP Review notes the company is seeking damages from vaccines "worth billions" .
The lawsuits seek monetary damages (reasonable royalties) rather than injunctions, consistent with the approach other plaintiffs have taken in this patent landscape .
Broader mRNA Patent Dispute Landscape
Sanofi's suits are the latest escalation in a dense web of high-stakes mRNA patent litigation that has been running for years. Key ongoing and recent disputes include:
Dispute
Status
Moderna v. Pfizer/BioNTech (filed Aug. 2022)
Moderna sued Pfizer/BioNTech for infringing three patents covering the 1-methylpseudouridine mRNA modification and broad mRNA/LNP technology . Partially paused in 2024 while the USPTO reviews patent validity . The case is ongoing in the U.S. and Europe; the UK Supreme Court appeal was docketed in 2025 .
Genevant & Arbutus v. Pfizer/BioNTech (filed 2023)
Alleges Pfizer/BioNTech's LNP technology infringes Genevant/Arbutus patents. Still in progress .
Alnylam v. Pfizer & Moderna
Filed over LNP-related patents; settled after adverse decisions against Alnylam's claims .
Moderna's $2.25B settlement with Arbutus/Genevant (March 2026)
Moderna agreed to pay up to $2.25 billion — $950M upfront (due July 2026) plus up to $1.3B contingent on an appeal — to settle LNP patent disputes, clearing a major overhang . Notably, no future royalties are owed on Moderna's future vaccines .
CureVac v. Moderna (filed April 2026)
CureVac sued Moderna for infringement of mRNA technology patents .
BioNTech v. Moderna (filed Feb. 2026)
BioNTech countersued Moderna in a separate action .
Pfizer/BioNTech's challenge at the EPO
In July 2025, the European Patent Office upheld a key Moderna patent, a win for Moderna in the European theater .
Key takeaway: Sanofi's lawsuits add a new front to what is already a multi-party, multi-jurisdictional war over foundational mRNA and LNP intellectual property. Every major mRNA vaccine player — Moderna, Pfizer/BioNTech, Sanofi/Translate Bio, CureVac, Arbutus, Genevant, Alnylam — is either suing or being sued, or both. The disputes cover three core technology pillars: mRNA sequence modifications (especially 1-methylpseudouridine), lipid nanoparticle delivery systems, and mRNA manufacturing/purification methods. Sanofi's entry specifically targets the LNP delivery and purification layer, which remains one of the most heavily contested areas in the entire landscape.
Translate Bio Inc. v. Moderna Inc. — No. 2:26-cv-08690
Translate Bio Inc. v. Pfizer Inc. — No. 2:26-cv-08697
Sanofi stated it is "seeking fair compensation for use of its patented technology" and is not seeking to block sales of any vaccines .
Specific Patents and Products Involved
Patents asserted: Sanofi alleges that Moderna's and Pfizer's vaccines infringe up to 10 patents held by Translate Bio covering core mRNA delivery technologies . The patents specifically relate to:
Lipid nanoparticle (LNP) compositions and methods for mRNA delivery — Translate Bio holds multiple patents on LNP manufacturing processes, including low-citrate-concentration encapsulation, ambient-temperature formulation, and pre-formed LNP mixing techniques .
mRNA purification technologies — additional patents covering how mRNA is purified for use in vaccines .
Products accused of infringement:
Moderna: Spikevax and mNexspike (both COVID-19 vaccines) and mResvia (RSV vaccine) .
Pfizer: Comirnaty (the COVID-19 vaccine co-developed with BioNTech) .
Royalties and Damages Being Sought
No fixed royalty percentage or specific dollar amount has been publicly disclosed in the complaints. Sanofi's position, per a spokesperson, is that it is seeking "fair compensation" for use of its patented technology . However, the damages at stake are enormous — the vaccines named have generated tens of billions of dollars in cumulative revenue, and Sanofi's Life Sciences IP Review notes the company is seeking damages from vaccines "worth billions" .
The lawsuits seek monetary damages (reasonable royalties) rather than injunctions, consistent with the approach other plaintiffs have taken in this patent landscape .
Broader mRNA Patent Dispute Landscape
Sanofi's suits are the latest escalation in a dense web of high-stakes mRNA patent litigation that has been running for years. Key ongoing and recent disputes include:
Dispute
Status
Moderna v. Pfizer/BioNTech (filed Aug. 2022)
Moderna sued Pfizer/BioNTech for infringing three patents covering the 1-methylpseudouridine mRNA modification and broad mRNA/LNP technology . Partially paused in 2024 while the USPTO reviews patent validity . The case is ongoing in the U.S. and Europe; the UK Supreme Court appeal was docketed in 2025 .
Genevant & Arbutus v. Pfizer/BioNTech (filed 2023)
Alleges Pfizer/BioNTech's LNP technology infringes Genevant/Arbutus patents. Still in progress .
Alnylam v. Pfizer & Moderna
Filed over LNP-related patents; settled after adverse decisions against Alnylam's claims .
Moderna's $2.25B settlement with Arbutus/Genevant (March 2026)
Moderna agreed to pay up to $2.25 billion — $950M upfront (due July 2026) plus up to $1.3B contingent on an appeal — to settle LNP patent disputes, clearing a major overhang . Notably, no future royalties are owed on Moderna's future vaccines .
CureVac v. Moderna (filed April 2026)
CureVac sued Moderna for infringement of mRNA technology patents .
BioNTech v. Moderna (filed Feb. 2026)
BioNTech countersued Moderna in a separate action .
Pfizer/BioNTech's challenge at the EPO
In July 2025, the European Patent Office upheld a key Moderna patent, a win for Moderna in the European theater .
Key takeaway: Sanofi's lawsuits add a new front to what is already a multi-party, multi-jurisdictional war over foundational mRNA and LNP intellectual property. Every major mRNA vaccine player — Moderna, Pfizer/BioNTech, Sanofi/Translate Bio, CureVac, Arbutus, Genevant, Alnylam — is either suing or being sued, or both. The disputes cover three core technology pillars: mRNA sequence modifications (especially 1-methylpseudouridine), lipid nanoparticle delivery systems, and mRNA manufacturing/purification methods. Sanofi's entry specifically targets the LNP delivery and purification layer, which remains one of the most heavily contested areas in the entire landscape.
pmc.ncbi.nlm.nih.govThe patent dispute over the breakthrough mRNA technology
reuters.comSanofi sues Pfizer, Moderna over COVID shot technology